Table 2.
Melanoma trials: selected conference abstracts
| Conference abstracts | Therapy | Phase | Patient (n) | PR% | medPFS (months) | mOS (months) | Year | Ref |
|---|---|---|---|---|---|---|---|---|
| BEAM Trial | Carboplatin, paclitaxel ± bevacizumab | (II) | 214 | 5.6 4.2 | 12.3 8.6 | 2009 | [92] | |
| Hodi et al. | Ipilimumab, bevacizumab | (I) | 22 | 36 | 2011 | [126] | ||
| BRIM 3 | Vemurafinib vs dacarbazine | (III) | 675 | 48 vs 5.5 | 5.3 vs 6.1 | 84% vs 64% at 1 year | 2011 | [127] |
PR - Partial Response, medPFS – median Progression Free Survival, TTP - Time to Progression, mOS – median Overall Survival